New combo aims to tame harsh side effects of advanced breast cancer treatment

NCT ID NCT05520723

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tested whether adding two supportive drugs (loperamide for diarrhea and G-CSF for low white blood cells) could make a common chemotherapy drug, sacituzumab govitecan, easier to tolerate. It involved 50 adults with advanced triple-negative or luminal breast cancer that had stopped responding to prior treatments. The main goal was to see if these additions reduced severe diarrhea and neutropenia during the first two treatment cycles.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hospital Arnau de Vilanova

    Lleida, Lleida, Spain

  • Hospital Quiron San Camilo- Ruber Juan Bravo

    Madrid, Madrid, 28006, Spain

  • Hospital Quirón Valencia

    Valencia, Valencia, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario A Coruña

    A Coruña, A Coruna, Spain

  • Hospital Universitario Clínico San Cecilio de Granada

    Granada, Spain

  • Hospital Universitario Donostia

    San Sebastián, Donostia, 20014, Spain

  • Hospital Universitario General de Catalunya

    Sant Cugat del Vallès, Barcelona, 08190, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital de Sant Joan Despí - Moises Broggi

    Barcelona, Spain

Conditions

Explore the condition pages connected to this study.